Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19.

José Ángel García-GarcíaMarta Pérez-QuintanaConsuelo Ramos-GiráldezIsabel Cebrián-GonzálezMaría L Martín-Ponce José Del Valle-VillagránMaría A Navarro-PuertoJorge Sánchez-VillegasRocío Gómez-HerrerosIsabel Manoja-BustosDaniel León-MartíLucía Serrano-RodríguezAlejandra de Miguel-AlbarrealMaría J Velasco-RomeroFrancisco Mula-FalcónPilar Fernández-PérezIsabel Melguizo-MoyaMaría J Pérez-QuintanaGuillermo Romero-MolinaSalvador Vergara-LópezJosé L Marenco-de la FuenteJorge Marín-MartínJosé A Mira-Escarti

Published in: Journal of clinical medicine (2021)

Similar mortality is observed in patients treated with anakinra or baricitinib plus corticosteroids.

Keyphrases

end stage renal disease
ejection fraction
coronavirus disease
sars cov
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
type diabetes
risk factors
cardiovascular events
cardiovascular disease
coronary artery disease
patient reported